Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-27

Clinical Trial Update: The Women TAF-FTC Benchmark Study [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating the emtricitabine/tenofovir alafenamide combination in women has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Emtricitabine/Tenofovir Alafenamide (emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: University of Washington | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-10-27